Protein plays a central role in biological systems, where various complex physiological activities and cellular responses to external stimuli rely on the interactions among proteins, forming intricate signaling networks. Protein-Protein Interactions (PPIs) involve the formation of stable protein complexes or transient interactions. The transient interactions between proteins often play crucial physiological roles. PPIs are predominantly dynamic processes that can change with time, cell cycle progression, or tissue type. They can also be influenced by factors such as post-translational modifications and protein conformational changes, exhibiting characteristics like transient nature, weak interactions, and multifactorial regulation. Several methods have been developed to study PPIs, including yeast two-hybrid assays and tandem affinity purification. For stable PPIs, biochemical methods relying on affinity purification are reliable and widely used. Tandem affinity purification, involving two sequential affinity purifications using two tags, improves the specificity of purification products. However, it may miss some transient or weak interactions. High-throughput screening methods based on the affinity of PPIs have also been developed. The yeast two-hybrid system is the most widely used for identifying candidate interaction partners of a given target protein. This yeast-based method has been adapted for use in mammalian cells. However, the yeast two-hybrid system suffers from high false-positive and negative results.
Select Service
A novel method for screening PPIs involves proximity labeling by modifying enzymes, enabling the detection of transient and weak interactions. By fusing modifying enzymes with proteins of interest, nearby proteins potentially interacting with the target protein can be labeled. Examples of such techniques include the selective protein proximity labeling using horseradish peroxidase (HRP), engineered ascorbate peroxidase (APEX), and proximity-dependent biotin identification (BioID). BioID technology offers significant advantages over traditional protein interaction discovery methods and is suitable for identifying transient, weak interactions, insoluble cellular structures, and dynamic processes within organisms.
What is BioID Technology?
BioID technology, short for Biotin Identification, is a cutting-edge method utilized to explore protein-protein interactions within living cells. Unlike traditional techniques that often struggle to capture transient or weak interactions, BioID offers a proximity-based labeling approach that overcomes many of these limitations.
At the core of BioID is a fusion protein comprising a protein of interest (POI) and a promiscuous biotin ligase known as BirA*. This fusion protein is expressed within the cellular environment, where BirA* enzymatically biotinylates nearby proteins. The biotinylated proteins can then be selectively isolated using avidin or streptavidin affinity purification techniques.
BioID (Varnaitė et al., 2016).
The hallmark of BioID lies in its ability to label proteins in close proximity to the POI, enabling the capture of both stable and transient interactions. This proximity-based labeling offers several advantages over traditional methods:
- Proximity Labeling: BioID capitalizes on the spatial proximity of proteins within the cellular environment. As BirA* enzymatically biotinylates proteins in its vicinity, it allows for the capture of interacting partners, regardless of the strength or duration of the interaction.
- In Vivo Compatibility: BioID is conducted within living cells, preserving the native cellular environment and enabling the study of protein interactions in their physiological context. This in vivo compatibility enhances the relevance and accuracy of the findings.
- Versatility: BioID is adaptable to various experimental settings and can be applied to study a wide range of biological processes. Whether investigating signaling pathways, protein complexes, or dynamic interactions, BioID offers a versatile platform for probing protein interactions.
- High Sensitivity: By biotinylating proteins in close proximity to the POI, BioID exhibits high sensitivity in detecting interacting partners. This sensitivity allows for the identification of low-abundance or transient interactors that may be missed by other methods.
- Quantitative Insights: BioID can provide quantitative insights into the relative proximity of proteins to the POI. By comparing the abundance of biotinylated proteins under different conditions or across different cellular compartments, researchers can gain valuable insights into the dynamics of protein interactions.
Applications of BioID in Cancer Research
Cancer is a complex and heterogeneous disease characterized by dysregulated cellular processes, including aberrant protein-protein interactions (PPIs). Understanding the molecular mechanisms driving cancer initiation, progression, and therapeutic resistance requires comprehensive insights into the protein interaction networks involved. BioID technology has emerged as a valuable tool in cancer research, offering unique advantages for the study of protein interactions implicated in oncogenesis and tumor progression.
Characterization of Oncogenic Signaling Pathways:
BioID facilitates the elucidation of oncogenic signaling pathways by identifying proximal protein interactors of key oncogenes. For instance, the Ras family of oncogenes (HRAS, NRAS, and KRAS) play pivotal roles in driving cell proliferation and survival in various cancers. By fusing BirA* to Ras proteins, researchers can identify novel interactors involved in Ras-mediated oncogenic signaling, shedding light on potential therapeutic targets.
Discovery of Novel Biomarkers and Therapeutic Targets:
BioID enables the discovery of novel biomarkers and therapeutic targets for cancer treatment. Through the identification of protein interactors associated with oncogenes or tumor suppressors, BioID can unveil candidate proteins involved in tumor initiation, progression, and metastasis. These identified proteins may serve as diagnostic biomarkers or therapeutic targets for precision oncology approaches.
Investigation of Tumor Suppressor Networks:
Tumor suppressor proteins play critical roles in maintaining genomic stability and preventing cancer development. BioID allows researchers to probe the protein interaction networks of tumor suppressors, such as P53, PTEN, and BRCA1/2, in cancer cells. By identifying interacting partners of tumor suppressors, BioID facilitates the elucidation of signaling pathways dysregulated in cancer and the identification of potential vulnerabilities for targeted therapy.
Exploration of Drug Resistance Mechanisms:
BioID can be employed to investigate mechanisms of drug resistance in cancer cells. By profiling protein interactions in drug-resistant cancer cell lines or patient-derived samples, researchers can identify changes in protein interaction networks associated with drug resistance. This information may lead to the discovery of alternative therapeutic targets or combination therapies to overcome drug resistance.
Functional Annotation of Cancer Genomes:
BioID can provide functional insights into cancer genomes by mapping the protein interaction networks of mutated or dysregulated genes. Integrating BioID data with genomic sequencing data allows for the prioritization of candidate driver mutations and the identification of downstream effectors contributing to tumorigenesis.
Validation of Protein-Protein Interactions in Physiological Contexts:
BioID enables the validation of protein-protein interactions in physiological contexts, including cancer-relevant cell lines or patient-derived samples. By confirming the proximity of proteins in cancer cells, BioID validates the relevance of identified interactions in the disease context, providing confidence in the functional significance of the findings.
Challenges and Future Directions
Despite its remarkable utility, BioID technology faces several challenges and opportunities for future development in the field of cancer research. Addressing these challenges and capitalizing on emerging opportunities will further enhance the applicability and efficacy of BioID in elucidating the complexities of cancer biology. Below are detailed discussions of the challenges encountered and potential future directions for BioID technology:
Non-specific Labeling and False Positives:
A significant challenge associated with BioID is the potential for non-specific labeling and false positives, particularly within the vicinity of the BirA* fusion protein. The indiscriminate biotinylation of proximal proteins may lead to the identification of non-relevant interactors, confounding data interpretation. Mitigating this challenge requires the development of strategies to enhance the specificity of biotinylation and reduce non-specific labeling events. Future advancements may involve the engineering of BirA* variants with improved target recognition specificity or the implementation of orthogonal labeling techniques to corroborate BioID findings.
Quantitative Assessment of Protein Interactions:
Another critical aspect for advancing BioID technology is the development of quantitative methods to assess the strength and dynamics of protein interactions. Traditional BioID experiments primarily provide qualitative insights into protein proximity but lack quantitative information regarding interaction affinities and kinetics. Future efforts should focus on integrating BioID with quantitative proteomic approaches, such as stable isotope labeling by amino acids in cell culture (SILAC) or targeted mass spectrometry, to quantitatively measure protein interactions and dynamics in cancer cells. This will enable researchers to elucidate the hierarchical organization of protein interaction networks and prioritize functionally relevant interactions for further investigation.
Miniaturization and High-Throughput Screening:
The miniaturization of BioID assays and the development of high-throughput screening platforms are essential for expanding the scope and scalability of BioID-based studies in cancer research. Current BioID protocols often require labor-intensive procedures and large cell culture volumes, limiting their applicability for large-scale screening endeavors. Future advancements may involve the automation of BioID workflows and the implementation of microfluidic-based platforms for parallelized and high-throughput protein interaction profiling. These technological innovations will enable rapid screening of protein interactomes across diverse cancer models and facilitate the discovery of novel biomarkers and therapeutic targets.
Integration with Multi-omics Approaches:
To gain comprehensive insights into the molecular mechanisms driving cancer pathogenesis, there is a growing need to integrate BioID data with other omics datasets, such as genomics, transcriptomics, and epigenomics. By correlating protein interaction networks with genomic alterations, gene expression profiles, and chromatin states in cancer cells, researchers can unravel the functional consequences of genetic and epigenetic dysregulation on protein interaction dynamics. Integrative multi-omics analyses will elucidate the crosstalk between different layers of molecular regulation in cancer cells and uncover novel regulatory networks governing oncogenic processes.
Exploration of Spatial Proteomics:
The spatial organization of protein complexes within subcellular compartments plays a crucial role in dictating their functions and regulatory mechanisms. Future directions for BioID technology involve the integration of spatial proteomics approaches, such as proximity-dependent biotinylation coupled with subcellular fractionation or super-resolution microscopy, to elucidate spatially resolved protein interaction networks in cancer cells. By mapping the subcellular localization of protein complexes and their dynamic relocalization in response to signaling cues or cellular perturbations, researchers can uncover spatially restricted regulatory circuits underlying cancer phenotypes.
Reference
- Varnaitė, Renata, and Stuart A. MacNeill. "Meet the neighbors: Mapping local protein interactomes by proximity‐dependent labeling with BioID." Proteomics 16.19 (2016): 2503-2518.
